Clinical application of varying drug-eluting stents for the treatment of acute myocardial infarction among Chinese population
10.3969/j.issn.1673-8225.2009.52.017
- VernacularTitle:不同药物支架在急性心肌梗死临床治疗中的应用:中国人群比较
- Author:
Yi MA
;
Xiaoming SHANG
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2009;13(52):10287-10290
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Sirolimus and Paclitaxel-eluting stents are commonly used for clinical application.Sirolimus-eluting stent have been proved safely and effectively to treat acute myocardial infarction.However,the comparison between those two eluting stents has been less reported yet.OBJECTIVE:To compare the security and long-term efficacy between Sirolimus- and Paclitaxel-eluting stents to the treatment of ST-segment acute myocardial infarction via percutaneous transluminal coronary intervention.METHODS:A total of 354 patients with ST-segment acute myocardial infarction,including 259 males and 95 females,were administrated with Sirolimus- and Paclitaxel-eluting stents.All cases were randomly divided into Sirolimus-elutin9 stent group (n=213) and Paclitaxel-eluting stent group (n=141).Major adverse cardiovascular events were compared between the two groups during 1-year following up.RESULTS AND CONCLUSION:One-year following up indicated that there was no significant difference in recurrent myocardial infarction (1.5% vs.1.5%) and cardiac death (2.5% vs.3.0%) between the two groups.Radiography showed that there was no significant difference in restenosis rate (5.0% vs.4.5%) between the two groups.Inner diameter lose was (0.19±0.34) mm in the Sirolimus-eluting stent group and (0.19±0.37) mm in the Paclitaxel-eluting stent group,and there was no significant difference.Additionally,there was also no significant difference in major adverse cardiovascular events between the two groups (8.9% vs.9.1%,P>0.05),suggesting that both Sirolimus-and Paclitaxel-eluting stents were safe and effective to the treatment of ST-segment acute myocardial infarction via percutaneous transluminal coronary intervention.
